Autres langues Puma Biotechnology, Inc.

Actions

PBYI

US74587V1070

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
4,95 ^USD	-2,37%		+2,48%	+14,32%

20/03	Puma Biotechnology prévoit de commencer une étude combinée sur le cancer du sein au second semestre ; les actions augmentent	MT
20/03	Puma Biotechnology, Inc. annonce que la FDA l'autorise à poursuivre son IND pour l'Alisertib dans le traitement du cancer du sein métastatique HER2-négatif et à récepteurs hormonaux positifs.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results	18/04
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)	04/04
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	03/04
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	20/03
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03
Puma Biotechnology : Corporate Presentation	06/03
Puma Biotech: Q4 Earnings Snapshot	29/02
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	29/02
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results	29/02
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	29/02
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	28/02
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference	22/02
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	15/02
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13/02
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13/02
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference	11/01
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	11/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Puma Biotechnology, Inc.

Actions

PBYI

US74587V1070

Autres langues

Filtres